FilingReader Intelligence
Piramal Pharma revenue falls 1% in Q1
July 28, 2025 at 07:05 PM UTC•By FilingReader AI
Piramal Pharma reported Q1 FY26 consolidated revenue of INR 1,934 crore, down 1% from the previous year, primarily due to destocking in a large CDMO product.
EBITDA stood at INR 165 crore with a 9% margin. The company maintains its FY2030 targets of tripling EBITDA and doubling revenues to over $2 billion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:PPLPHARMA•Bombay Stock Exchange
News Alerts
Get instant email alerts when PIRAMAL PHARMA publishes news
Free account required • Unsubscribe anytime